title: Investor Outlook: After the Biotech Bubble Popped.
abstract: After a few torrid years of value appreciation, the biotech "bubble" has precipitously popped over the past few months. In this report, we take a look at some of the factors that drove the run-up in valuations, the triggers that led to their substantial pullback, and where the industry may be headed from here. Gene therapy/editing companies have been particularly affected by these dynamics, raising a new set of questions and challenges for the group.
authors.affiliation: Piper Jaffray & Co. , New York, New York.
authors.forename: Joshua
authors.initials: J
authors.lastname: Schimmer
authors.affiliation: Piper Jaffray & Co. , New York, New York.
authors.forename: Steven
authors.initials: S
authors.lastname: Breazzano
authors.affiliation: Piper Jaffray & Co. , New York, New York.
authors.forename: Jerry
authors.initials: J
authors.lastname: Yang
mesh_terms: D001709:Biotechnology / Q000191:economics*; D015316:Genetic Therapy / Q000191:economics*; D007449:Investments / Q000191:economics*